checkAd

    THERACLION  273  0 Kommentare 2018 Annual Results

    Regulatory News:

    THERACLION (ISIN: FR0010120402; Ticker: ALTHE, eligible for the PEA-PME equity investment plan), an innovative company specializing in the development of medical equipment for echotherapy, notably for varicose veins, announces today its annual results 2018 ended 31 December 2018.

    David Caumartin, CEO of Theraclion, declares: "After the announcement on February 12, 2019 of the financing agreement of € 4.8 million to be raised to € 11.8 million, the publication of the 2018 annual resultsmakes it possible to shine a light on another line of work undertaken in recent months: a strong and lasting reduction in the cost structure, in the order of € 1 million per year. Theraclion has now a financial structure and a cost structure adapted to its development. Our echotherapy solution is gradually adopted by specialists. Nearly 800 treatments were performed in 2018, up 45%. The threshold of 2,000 cumulative treatments for historical pathologies, thyroid nodules and breast adenofibroma has been crossed. In 2019, Theraclion will capitalize on its historical know-how to deploy its technology on varicose vein treatment and offer an innovative solution: non-invasive, without postoperative pain and without anesthetist."

    Results of Theraclion SA in 2018

    In thousands of euros   31/12/2018   31/12/2017   Change
    Sales   1,928   2,429   -21%
    Subsidies 11 393 -97%
    Other revenues   1   0   n.a.
    Total operating revenue   1,940   2,822   -31%
    Purchases of goods (1,080) (1,436) -24%
    External costs (3,386) (3,790) -10%
    Personnel costs (3,766) (4,104) -8%
    Other operating expenses   (685)   (592)   16%
    Total operating costs   (8,918)   (9,922)   -10%
    Operating income/(loss)   (6,977)   (7,098)   -2%
    Net financial items (274) (256) 7%
    Net non-recurring items (72) (18) 300%.
    Research tax credit   1,179   1,148   3%
    Net income/(loss)   (6,144)   (6,224)   -1%
                 
    Average headcount (FTE)   29   32   -9%
     

    Accounts approved by the Board of Directors on March 18, 2019. The audit procedures for the financial statements for fiscal year 2018 have been completed and the certification report will be issued after verification of the management report.

    Seite 1 von 4



    Business Wire (engl.)
    0 Follower
    Autor folgen

    THERACLION 2018 Annual Results Regulatory News: THERACLION (ISIN: FR0010120402; Ticker: ALTHE, eligible for the PEA-PME equity investment plan), an innovative company specializing in the development of medical equipment for echotherapy, notably for …